Citeline analysts Millie Gray and Flora Mackay take a look at the high-impact abstracts, presented at ESMO 2023. They also address the most practice-changing data, putting it into context, and cover indications including HR+/HER- breast cancer, bladder cancer, gastric cancer, prostate cancer, NSCLC, and more.
